Xeris Biopharma
Most recent annual filing: 2026-03-02
- XP-8121 Ph3 start2H 2026XP-8121 Ph3 start, 2H 2026, routine
- Isturisa relacorilant FDA decisionDec 17, 2026Isturisa relacorilant FDA decision, Dec 17, 2026, material
- XP-8121 corporate update2028XP-8121 corporate update, 2028, routine
- 2028 Convertible Notes / HayfinJan 15, 20282028 Convertible Notes / Hayfin, Jan 15, 2028, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
Gvoke
glucagonKeveyis
dichlorphenamidelevothyroxine
XP-8121Technology platforms
XeriSol
Proprietary non-aqueous formulation technology designed to enable room-temperature stable, ready-to-use injectable formulations of peptide and small molecule drugs; used in Gvoke commercially and in clinical trials for XP-8121; available for partnership licensing across therapeutic areas
XeriJect
Proprietary non-aqueous viscoelastic pharmaceutical suspension technology enabling small-volume subcutaneous injections of large molecules including proteins, monoclonal antibodies, and vaccines; available for partnership licensing across therapeutic areas
Biotech Distilled coverage (3)
- 2026-09-09 UPDATE: Xeris Biopharma (XERS) — The Levothyroxine Trial Is Designed to Tie, Not to Win 🔒 Paid
- 2026-08-07 UPDATE: Xeris Biopharma (XERS) — Five Filers, One Trial Date, and a Convertible That Finally Died 🔒 Paid
- 2026-07-23 Xeris Biopharma (XERS) — Scientific Deep Dive for Recorlev, XP-8121, and the XeriSol/XeriJect Platform 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.